Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
6.20
-2.19 (-26.10%)
At close: Nov 13, 2026, 4:00 PM EST
6.10
-0.10 (-1.61%)
After-hours: Nov 13, 2026, 7:55 PM EST

Candel Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
----0.130.13
Revenue Growth
----0%0%
Cost of Revenue
----20.3514.59
Gross Profit
-----20.22-14.47
Selling, General & Admin
26.3118.4214.614.4114.511.26
Research & Development
55.4529.7618.7323.59--
Operating Expenses
81.7648.1833.333814.511.26
Operating Income
-81.76-48.18-33.33-38-34.72-25.73
Interest Expense
-6.15-2.12-2.09-2.6-1.71-0.05
Interest & Investment Income
5.913.921.092.081.22-
Other Non Operating Income (Expenses)
-17.148.29-20.80.9716.42-10.81
EBT Excluding Unusual Items
-99.13-38.09-55.14-37.55-18.79-36.59
Asset Writedown
-0.01-0.09-0.04-0.39--
Other Unusual Items
-----0.46
Pretax Income
-99.14-38.18-55.18-37.94-18.79-36.12
Net Income
-99.14-38.18-55.18-37.94-18.79-36.12
Net Income to Common
-99.14-38.18-55.18-37.94-18.79-36.12
Net Income Growth
------
Shares Outstanding (Basic)
675332292919
Shares Outstanding (Diluted)
675332292919
Shares Change
39.72%67.19%9.47%0.39%52.72%62.49%
EPS (Basic)
-1.47-0.72-1.74-1.31-0.65-1.91
EPS (Diluted)
-1.47-0.72-1.74-1.31-0.65-1.91
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-70.2-38.9-27.04-34.7-32.72-24.05
Free Cash Flow Per Share
-1.04-0.73-0.85-1.20-1.14-1.27
Operating Margin
-----27777.60%-20580.80%
Profit Margin
-----15035.20%-28899.20%
Free Cash Flow Margin
-----26172.80%-19242.40%
EBITDA
-81.1-47.33-32.34-37.04-33.94-25.49
D&A For EBITDA
0.650.850.990.960.780.23
EBIT
-81.76-48.18-33.33-38-34.72-25.73
SEC Filings: 10-K · 10-Q